A clinical trial with dipropylacetate (DPA), a new anti‐epileptic drug (Dépakine®, Ergenyl®) is reported in 116 patients. Primarily generalized epilepsies ‐ petit mal of different types and centrencephalic grand mal ‐ were mainly benefited. Less favourable results were obtained in epilepsy of focal origin. The side effects were usually minimal, consisting of gastric disturbances. Dipropylacetate increased the effect of other anti‐epileptics, especially barbiturates, primidone and benzodiazepines. Some patients were more alert and their behaviour improved on DPA.

Dipropylacetate (DPA) is a new anti-epileptic drug that mainly benefits generalized epilepsies and increases the effect of other drugs, with minimal side effects.

Paper

Dipropylacetate (Depakine®, Ergenyl®) in the Treatment of Epilepsy

References

Citations